TRANSFUSION MEDICINE AND IMMUNOHEMATOLOGY: Edited by Karina YazdanbakhshNovel blood derived hemostatic agents for bleeding therapy and prophylaxisHegde, Shailajaa; Zheng, Yib; Cancelas, Jose A.a,b Author Information aHoxworth Blood Center, University of Cincinnati Academic Health Center bCincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA Correspondence to Jose A. Cancelas, MD, PhD, Hoxworth Blood Center, University of Cincinnati Academic Health Center, 3130 Highland Ave, Cincinnati, OH 45267, USA. Tel: +1 513 558 1324; e-mail: [email protected] Current Opinion in Hematology: November 2022 - Volume 29 - Issue 6 - p 281-289 doi: 10.1097/MOH.0000000000000737 Buy Metrics Abstract Purpose of review Hemorrhage is a major cause of preventable death in trauma and cancer. Trauma induced coagulopathy and cancer-associated endotheliopathy remain major therapeutic challenges. Early, aggressive administration of blood-derived products with hypothesized increased clotting potency has been proposed. A series of early- and late-phase clinical trials testing the safety and/or efficacy of lyophilized plasma and new forms of platelet products in humans have provided light on the future of alternative blood component therapies. This review intends to contextualize and provide a critical review of the information provided by these trials. Recent findings The beneficial effect of existing freeze-dried plasma products may not be as high as initially anticipated when tested in randomized, multicenter clinical trials. A next-generation freeze dried plasma product has shown safety in an early phase clinical trial and other freeze-dried plasma and spray-dried plasma with promising preclinical profiles are embarking in first-in-human trials. New platelet additive solutions and forms of cryopreservation or lyophilization of platelets with long-term shelf-life have demonstrated feasibility and logistical advantages. Summary: Recent trials have confirmed logistical advantages of modified plasma and platelet products in the treatment or prophylaxis of bleeding. However, their postulated increased potency profile remains unconfirmed. Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.